drugset / Trial / NCT00004799
Phase III Randomized, Double-Blind, Placebo-Controlled Study of Acellular and Whole-Cell Pertussis Vaccines
Phase 3
Completed
10000 enrolled
National Institute of Allergy and Infectious Diseases (NIAID)
National Bacteriological Laboratory · collab
RandomizedDouble-blindPrevention
Summary
OBJECTIVES: I. Compare the safety and efficacy of acellular 2-component vs. acellular multicomponent vs. whole-cell pertussis vaccine vs. placebo in infants living in Sweden. II. Compare the relative protection of each vaccine against atypical or subclinical pertussis infection. III. Analyze possible laboratory correlates to vaccine protection.
Timeline
- Start
- 1991-04
- Primary completion
- —
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | diphtheria-tetanus vaccine | Vaccine | — | Intramuscular |
| Subject | whole-cell pertussis vaccine | Vaccine | — | Intramuscular |